116results about How to "Reduce nephrotoxicity" patented technology

The present invention provides new aminoglycoside dosing regimens associated with enhanced microbicidal activity and reduced nephrotoxicity, as well as methods of using these dosing regimens to treat various bacterial infections.

Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.

The invention relates to a pharmaceutical preparation which consists of or contains cyclosporin A, an emulsifying .alpha.-tocopherol derivative, an ethoxylation product of vegetable oils, fatty acids or fats as a further emulsifier and a pharmaceutically customary alcohol.

The present invention relates to a method of treating cancer in a patient comprising administering to the patient intraperitoneally, a cancer treating effective amount of a lipid-based platinum compound formulation.

The invention includes compositions comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a composition of the invention with a human patient.

The invention belongs to the technical field of medicines, relates to a paclitaxel medicinal composition and a preparation method thereof, and in particular relates to an injection paclitaxel nanocrystal preparation and a preparation method thereof as well as application of the preparation for preparing anti-tumor medicines. The paclitaxel nanocrystal belongs to a nano preparation, is small in grain diameter and good in stability, and cannot be easily separated, so that the dissolubility of paclitaxel is remarkably improved, and in-vivo studies prove that the paclitaxel nanocrystal has certain targeting performance, and can be used in anti-tumor treatment.

Improved devices, systems, and methods treatment of patients can be used to help mitigate injury to the kidneys by applying cyclical mechanical pressure energy at low intensities. The energy often be selectively directed from non-invasive transducers disposed outside the patients. The energy will typically comprise low frequency ultrasound energy, shock wave energy, or the like, and may induce the generation and/or release of nitric oxide, thereby enhancing perfusion and ameliorating tissue damage. Superimposed micro and macro duty cycles may help avoid thermal and other injury to tissues of the patient during treatment. Bilateral treatments are facilitated by a support structure that orients at least one transducer toward each kidney.

The invention discloses an acylhydrazone schiff base-copper complex and complex nanoparticles composed of the acylhydrazone schiff base-copper complex and human serum albumin. The chemical formula of the acylhydrazone schiff base-copper complex is [CuBr(BA)(L)] or [CuBr(DMF)(L)], wherein BA is quinoline, L is a compound with a tridentate acylhydrazone schiff base structure, DMF is N,N-dimethyl formamide, and Br-, quinolone or DMF in the complex is coordinated with a copper center as ligands. As prodrugs, the complex nanoparticles composed of the acylhydrazone schiff base-copper complex and human serum albumin not only improve the activity of drugs, but also can reduce the toxicity of drugs, thus having good clinical application values.

The invention discloses a stable butylphthalide sodium chloride injection as well as a preparation method and application thereof, belongs to the technical field of pharmaceutical preparations, and solves the problems of poor safety and stability of the butylphthalide sodium chloride injection in the prior art. The stable butylphthalide sodium chloride injection comprises a sulfobutyl betacyclodextrin sodium compound, sodium chloride and water. The pH value of the butylphthalide sodium chloride injection is 4.0-5.0. The preparation method comprises the following steps of weighing a prescription amount of sulfobutyl betacyclodextrin sodium, and adding water for dissolving to prepare an auxiliary material solution; weighing a prescription amount of butylphthalide, adding the butylphthalide into the auxiliary material solution, stirring to enable the sulfobutyl betacyclodextrin sodium to include the butylphthalide, and adjusting the pH value of the solution to 4.0-5.0 after the inclusionof the butylphthalide is completed; and filtering, filling and sterilizing to obtain the product. The stable butylphthalide sodium chloride injection as well as the preparation method and applicationthereof are scientific in design and ingenious in thought, and the butylphthalide sodium chloride injection has good stability and safety.

The invention discloses an entecavir high-density lipoprotein enveloping preparation, and a preparation method and a use thereof. The entecavir high-density lipoprotein enveloping preparation contains entecavir, phospholipid, cholesterol and ApoAl in the weight ratio of 5: 7: 3: (5-20).

The invention relates to lysobactin amides and methods for their preparation, as well as their use for manufacturing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.

The present invention provides compositions and methods to reduce renal damage caused by nephrotoxic drugs. The invention provides compositions comprising an anionically substituted oligosaccharide, a nephrotoxic drug and a pharmaceutically acceptable carrier, where the oligosaccharide is present in an amount effective for substantially inhibiting the nephrotoxic effect of the drug.

The present invention refers to isoxazole derivatives, in particular diarylisoxazole derivatives inhibitors of cyclooxygenase (COX), in particular cyclooxygenase-1 (COX-1), to their pharmaceutical compositions, the process for their preparation and their use for the chemoprevention and treatment of inflammatory syndromes and in the prevention and treatment of carcinomas, in particular intestinal, ovarian and cutaneous carcinomas, in the treatment of pain syndromes, in particular after surgery, and in the cardiovascular field as antithrombotics/vasoprotectives/cardioprotectives.

The invention relates to an ibuprofen nanoparticle with low renal toxicity and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The nanoparticle is prepared by placing ibuprofen, a plant-derived functional natural product auxiliary material, a flow aid and ball-milling beads in a ball-milling tank and carrying out a co-grinding reaction at a certain rotating speed, and the ibuprofen is uniformly entrapped in a carrier under the action of mechanical force, so that an ibuprofen nanoparticle product with low renal toxicity is obtained. According to the ibuprofen nanoparticle and the method, the nanoparticle is prepared through a limited preparation method, the operation is simple, the use of an organic solvent is avoided, the problems about raw material loss, thermal decomposition and the like caused by solvent residues and a solvent thermal removal process are prevented, and the advantages of high preparation efficiency, safe and reliable production, low production cost, less pollution and the like are achieved; and meanwhile, a plant-derived macromolecule is adopted as the carrier, so that the renal toxicity of the ibuprofen is reduced while solubilization and synergism are achieved, and the macromolecule is of great importance to safe medication of a non-steroidal anti-inflammatory drug.

The present invention provides a conjugate of tenofovir, addy adefovir and intelligent polymers, a method for preparing the same, and an usage. The invention relates to the technical field that antiviral medicinal molecular tenofovir and addy adefovir are chemical modified, namely, phosphate group of tenofovir or addy adefovir is linked with X group, then X group is linked with intelligent polymers R, or phosphate group of tenofovir or addy adefovir is linked with intelligent polymers R with X function group, and a conjugate of tenofovir, addy adefovir and intelligent polymers with A-X-R-Y formula is formed. The modified tenofovir and addy adefovir forms efficient screen for raw medicine, and improves obviously medicine absorption of intestinal and absorption of cell, improves bioavailability of medicine, at the same time, reduces the kidney cleaning of medicine, and reduces the toxic for kidney, improves security.

The present invention relates to diagnostic and therapeutic nanoparticles. More particularly, the present invention relates to creating a hybrid gold/gold sulfide nanoparticle with a chitosan matrix surrounding the metallic nanoparticle and a method for making the same. The chitosan-coated gold/gold sulfide nanoparticles can then be incorporated with additional therapeutic or diagnostic compounds such as iodine, antibodies, or other suitable compounds. The nanoparticles of the present invention have the dual capabilities of absorbing near infrared wavelength light to (1) act as a therapeutic agent by generating heat energy effective for cell ablation or for release of therapeutic compounds embedded in the chitosan matrix and (2) creating diagnostic benefit by incorporation of X-ray or MRI contrast agents.